Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

Press Releases

Hunneberga Horse Stable to conduct pilot test of LAMPlify®

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces that Hunneberga Horse Stable (Hunneberga Hästgård) and Tomas Hammar, showjumping trainer and CEO at Hunneberga Horse Stable, has initiated a partnership with Diagonal Bio to conduct a pilot test. The agreement is set to three months and will involve a testing program of LAMPlify® to detect respiratory viral infections in showjumping horses during upcoming competitions. The pilot will start immediately.

Read more

Horse trainer Daniel Redén at StallZet will conduct a pilot with LAMPlify®

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has partnered with StallZet and Daniel Redén, one of Sweden’s leading horse trotting training facilities, to conduct a pilot test using LAMPlify® to detect respiratory viral infections in StallZet’s trotters. The three-month agreement takes effect immediately.

Read more

Diagonal Bio AB’s warrant exercise registered at the Swedish Companies Registration Office

Regulatory

Diagonal Bio AB (“Diagonal” or the “Company”) today announces that the new shares from the exercise of warrants of series TO 1 have been registered with the Swedish Companies Registration Office.

Read more

Diagonal Bio AB announces the outcome of the exercise of warrants of series TO 1

Regulatory

On September 26, 2024, the exercise period for Diagonal Bio AB’s (“Diagonal” or the “Company”) warrants of series TO 1 (“TO 1”) ended. A total of 77.794 warrants of series TO 1 have been exercised to subscribe for 77.794 shares, corresponding to gross proceeds of SEK 3.889,70.

Read more

The last day of trading in warrants of series TO 1 is on the 24th of September 2024

Non-regulatory

The 24th of September 2024 is the last day of trading in warrants of series TO 1, which were issued in connection with Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) preferential rights issue of units that was carried out earlier in 2024. The exercise period runs until the 26th of September 2024.

Read more

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 (0)8 913 008
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö